WILMINGTON, N.C. (May 16, 2022) – The PPD clinical research business of Thermo Fisher Scientific has been recognized for excellence in the 2022 CRO Leadership Awards. This is the 11th consecutive year the business has been honored through this award program, which is based on a survey of pharmaceutical and biotech professionals conducted for Clinical Leader and Life Science Leader magazines.
Recognized as a global industry leader, the business provides clinical development and analytical services from early development through regulatory approval and market access. The business helps customers accelerate development and lower costs from scientific idea to approved medicine, providing product lifecycle management to ensure data integrity and patient safety. Utilizing patient-centered strategies and data analytics, PPD clinical research services cover multiple therapeutic areas, all phases of clinical development, peri- and post-approval, patient recruitment, investigator sites, comprehensive laboratory services, innovative and decentralized trial designs, and a purpose-built delivery model for biotech customers.
In the 2022 CRO Leadership Awards, which recognize high-performing companies for exceptional customer service, the business earned recognition for its capabilities – including access to patient populations, data management and patient recruitment – and for compatibility, including responsiveness, project communications and customer service. In addition, the business was recognized for quality, reliability and expertise.
“For more than a decade, the CRO Leadership Awards have honored us for our clinical development and analytical services, which are backed by our firm commitment to quality to help customers deliver life-changing therapies,” said David Johnston, Ph.D., senior vice president and president, clinical research, Thermo Fisher Scientific. “Our customers benefit from our innovative scientific approaches and differentiated capabilities as we partner with them through every phase of the research process.”
The CRO Leadership Awards program is a partnership between Life Science Connect’s sister publications, Clinical Leader and Life Science Leader, and Industry Standard Research (ISR). Each year, they assess more than 50 contract research organizations (CROs) on multiple performance metrics in ISR’s annual CRO Quality Benchmarking survey. Survey participants included respondents from pharma and biotech companies who had worked directly with CROs in the prior 18 months. As an honoree, the PPD clinical research business will be featured in the 2022 CRO Leadership Awards issue in June.
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
Media Contact Information:
Clinical Research, Thermo Fisher Scientific
SOURCE Thermo Fisher Scientific
If you have any questions regarding this Press Release, please email us at firstname.lastname@example.org.